Gérald Marit

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste et al. · Blood · 2010 · 1.6K citations · Full text

Medicine, Hematology, Oncology +10

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Michel Attal, Valérie Lauwers‐Cancès, Gérald Marit et al. · New England Journal of Medicine · 2012 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

Hervé Avet‐Loiseau, Michel Attal, Philippe Moreau et al. · Blood · 2007 · 905 citations · Full text

Medicine, Genetics, Hematology +15

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

Michel Attal, Jean‐Luc Harousseau, Serge Leyvraz et al. · Blood · 2006 · 667 citations

Medicine, Hematology, Oncology +12

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Stéphane Picard, Karine Titier, Gabriel Étienne et al. · Blood · 2006 · 604 citations · Full text

Life Sciences, Hematology, Oncology +13